Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rhGM-CSF +/- WLL in PAP
NCT01983657Phase 2Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2012
- Primary completion
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in pulmonary alveolar proteinosis (PAP), sponsored by Shanghai Pulmonary Hospital. Status: unknown.
02
Drugs
sargramostim
03
Conditions
pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on NCT01983657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983657.